Across Europe, by 30 June 2016, the pharmaceutical industry will disclose payments made to health professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis for collaboration in the future. Industry is being proactive, based on its commitment to this relationship. Collaboration between industry and health professionals benefits patients. It is a relationship that has delivered numerous innovative medicines and changed the way many diseases impact on our lives. Industry and health professionals collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway. Society has increasingly high expectations for transparency, none more so than in healthcare. As a member of EFPIA, Pierre Fabre group want to ensure we meet those expectations complying with EFPIA Disclosure Code.
About the EFPIA Disclosure Code
The EFPIA Disclosure Code is a code of conduct that requires all EFPIA member companies and companies that are members of EFPIA member associations to disclose transfers of value to Healthcare Professionals (HCPs) and healthcare organizations (HCOs).
The first disclosures will be made by 30 June 2016, for payments made in 2015. For Pierre Fabre affiliates in Europe, Russia and Turkey, this information will be published on a public platform, which could be on a central national platform, combing data from different companies, on each affiliate company’s own website or, on the company’s corporate website when affiliate doesn’t have its own website (see after for these public disclosures).
Following European legislation on data privacy, recipients of published transfers of value have a right to access and correct personal data concerning them, which is exercisable by email.
For further information about the EFPIA disclosure code